Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 9 10 11 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
BioVersys–EU (govt): credit, 202104– venture debt loan up to €20m in three tranches from EIB 2021-04-14
Quercis Pharma–Rx Communications: public relations, 202104 service existent IR by Rx Communications Group 2021-04-13
Repertoire Immune Medicines–SEVERAL: investment, 202104 financing round Series B $189m incl Flagship Pioneering + Softbank + PSP Investments et al 2021-04-13
Siemens–Biognosys: MS-based biomarker discovery, 202104– strategic agreem marker discovery using HRM-MS for Dx assay development with S Healthineers 2021-04-13
ImmunOs Therapeutics–EU (govt): grant, 202104– Eurostars-2 grant for developm of OCi antibody tog with ProteoGenix SAS + Amsterdam UMC 2021-04-12
Mestex–Grünenthal: investment, 202104 acquisition 100% of Mestex AG by Grünenthal 2021-04-12
VectivBio–SEVERAL: investment, 202104 IPO $127.5m+$19.125m with 7.5m+1.125m ordinary shares at $17/share at Nasdaq Global Market 2021-04-08
Delta 4–OTHER: investment, 202104 financing round Series A €multi-million closing with addit funding from European Family Office 2021-04-07
Delta 4–SEVERAL: investment, 202104 financing round Series A €multi-million closing with addit funding from European Family Office 2021-04-07
Metagenomi–SEVERAL: investment, 202104 financing round Series A extension $10m with RA Capital Management closing total Series A at $75m 2021-04-07
Stimit–Dräger: investment, 202104 acquisition of majority share in Stimit AG by Drägerwerk AG & Co KGaA 2021-04-01
Celeris Therapeutics–Longevitytech.fund: investment, 202103 pre-seed financing round totalling €400k incl investor Longevitytech.fund 2021-03-31
Celeris Therapeutics–R42 Group: investment, 202103 pre-seed financing round totalling €400k incl investor R42 Group 2021-03-31
Celeris Therapeutics–SEVERAL: investment, 202103 pre-seed financing round €400k from R42 Group + Longevitytech.fund 2021-03-31
OncoResponse–Helsinn: investment, 202103 financing round Series C totalling $40.6m incl existing + co-investor 3B Future Health Fund 2021-03-31
OncoResponse–SEVERAL: investment, 202103 financing round Series C $40.6m led by Magnetar Group 2021-03-31
Pyxis Oncology–Bayer: investment, 202103 financing round Series B totalling $152m incl existing + co-investor Leaps by Bayer 2021-03-30
Pyxis Oncology–HBM: investment, 202103 financing round Series B totalling $152m incl new + co-investor HBM Healthcare Investments 2021-03-30
Pyxis Oncology–SEVERAL: investment, 202103 financing round Series B $152m led by Arix Bioscience 2021-03-30
Allcyte–42cap: investment, 202103 seed financing round totalling $6m incl new investor 42cap 2021-03-25
Allcyte–Air Street Capital: investment, 202103 seed financing round totalling $6m incl new investor Air Street Capital 2021-03-25
Allcyte–Amino Collective: investment, 202103 seed financing round totalling $6m incl new investor Amino Collective 2021-03-25
Allcyte–PUSH Ventures: investment, 202103 seed financing round totalling $6m incl new investor PUSH Ventures 2021-03-25
Allcyte–SEVERAL: investment, 202103 seed financing round $6m incl 42cap + Air Street Capital + PUSH Ventures et al 2021-03-25
Allcyte–VP Venture Partners: investment, 202103 seed financing round totalling $6m incl new investor VP Venture Partners 2021-03-25
Cytosurge–Univ Tübingen: genome editing, 202103 collab cell line developm using FluidFM nano-injection for single cell CRISPR gene engineering 2021-03-24
Formycon–Leukocare: biopharmaceuticals, 202103– collab Master Service Agreem developm stable formulations for biosimilars/biologics of Formycon 2021-03-24
Aktis Oncology–Novartis: investment, 202103 financing round Series A totalling $72m incl co-investor Novartis 2021-03-18
Aktis Oncology–SEVERAL: investment, 202103 financing round Series A $72m co-led by MPM Capital + EcoR1 Capital + Vida Ventures 2021-03-18
Indivumed–Live Wire Strategic Communications: public relations, 202103 service existent by Live Wire 2021-03-18
Amphista Therapeutics–SEVERAL: investment, 202103 financing round Series B £38m ($53m) co-led by Forbion + Gilde Healthcare 2021-03-17
GenMark–Roche: investment, 202103– acquisition $1.8b recommended cash tender offer at $24.05/share premium of 43% 2021-03-15
Monte Rosa Therapeutics–Aisling Capital: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Aisling Capital 2021-03-12
Monte Rosa Therapeutics–Alphabet: investment, 202103 financing round Series C totalling $95m incl existing + co-investor GV 2021-03-12
Monte Rosa Therapeutics–Amzak Health: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Amzak Health 2021-03-12
Monte Rosa Therapeutics–Avoro Capital: investment, 202103 financing round Series C totalling $95m incl new + lead investor Avoro Capital Advisors 2021-03-12
Monte Rosa Therapeutics–BlackRock: investment, 202103 financing round Series C totalling $95m incl new + co-investor BlackRock 2021-03-12
Monte Rosa Therapeutics–Cambridge Asset Management: investment, 202103 financing round Series C totalling $95m incl existing + co-investor CAM 2021-03-12
Monte Rosa Therapeutics–Casdin Capital: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Casdin Capital 2021-03-12
Monte Rosa Therapeutics–Cormorant Asset Management: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Cormorant 2021-03-12
Monte Rosa Therapeutics–Fidelity: investment, 202103 financing round Series C totalling $95m incl new + co-investor Fidelity Management & Research Co 2021-03-12
Monte Rosa Therapeutics–HBM: investment, 202103 financing round Series C totalling $95m incl existing + co-investor HBM Healthcare Investments 2021-03-12
Monte Rosa Therapeutics–New Enterprise Associates: investment, 202103 financing round Series C totalling $95m incl existing + co-investor NEA 2021-03-12
Monte Rosa Therapeutics–RTW Investments: investment, 202103 financing round Series C totalling $95m incl new + co-investor RTW Investments 2021-03-12
Monte Rosa Therapeutics–SEVERAL: investment, 202103 financing round Series C $95m led by new investor Avoro Capital Advisors 2021-03-12
Monte Rosa Therapeutics–Sixty Degree Capital: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Sixty Degree 2021-03-12
Monte Rosa Therapeutics–T Rowe Price: investment, 202103 financing round Series C totalling $95m incl new + co-investor T Rowe Price Associates Inc 2021-03-12
Monte Rosa Therapeutics–Versant Ventures: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Versant Ventures 2021-03-12
Relief Therapeutics–OTHER: investment, 202103 private placement CHF10m with 41.5m shares at CHF0.2412/share with institutional US investor 2021-03-12
Agomab Therapeutics–Boehringer: investment, 202103 financing round Series B totalling $74m incl existing + co-investor BIVF 2021-03-10
Agomab Therapeutics–SEVERAL: investment, 202103 financing round Series B $74m led by new investor Redmile Group 2021-03-10
Agomab Therapeutics–Trophic Communications: public relations, 202103 service existent by Trophic Communications 2021-03-10
BellaSeno–Akampion: public relations, 202103 service existent by Akampion 2021-03-10
BellaSeno–Fraunhofer: implant production technology, 202103– collab developm automated resorbable implant production + QC with Fraunhofer IPT 2021-03-10
BellaSeno–Germany (govt): grant, 202103– KUM-innovativ grant totalling €1.4m tog with Fraunhofer IPT from BMBF 2021-03-10
BioPhero–Novo Group: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Novo Holdings 2021-03-09
BioPhero–SEVERAL: investment, 202103 financing round Series A $17m led by DCVC Bio with FMC Ventures + Syngenta Ventures + Novo Holdings 2021-03-09
BioPhero–Syngenta: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Syngenta Ventures 2021-03-09
Visus Therapeutics–SEVERAL: investment, 202103 financing round Series A $36m with JJDC + RTW Investments + Wille AG + existing investors 2021-03-09
Visus Therapeutics–Wille Finance: investment, 202103 financing round Series A totalling $36m incl investor Wille AG 2021-03-09
Lophius–Mikrogen: investment, 202103 acquisition of assets + technologies incl takeover of entire team + lab in Regensburg by Mikrogen 2021-03-08
Exscientia–BlackRock: investment, 202103 financing round Series C extension totalling $40m + closing at total of $100m incl new investor BlockRock 2021-03-04
Exscientia–SEVERAL: investment, 202103 financing round Series C extension $40m + closing at total of $100m with BlockRock joining existing investors 2021-03-04
Atai Life Sciences–KCSA Strategic Communications: public relations, 202103 service existent KCSA is media contact 2021-03-03
Atai Life Sciences–SEVERAL: investment, 202103 financing round Series D $157m co-led by Apeiron + Thiel Capital 2021-03-03
ActiTrexx–SEVERAL: investment, 202103 financing round Series A €3.5m led by LBBW Venture Capital GmbH 2021-03-02
Argobio–Evotec: investment, 202103 seed financing round totalling €50m committed capital incl investor Evotec 2021-03-02
Argobio–SEVERAL: investment, 202103 seed financing round €50m committed capital from Kurma + Bpifrance + Angelini Pharma + Evotec + Institut Pasteur 2021-03-02
eGenesis–Bayer: investment, 202103 financing round Series C totalling $125m incl existing investor Leaps by Bayer 2021-03-02
eGenesis–Fresenius: investment, 202103 financing round Series C totalling $125m incl existing investor Fresenius Medical Care Ventures 2021-03-02
eGenesis–HBM: investment, 202103 financing round Series C totalling $125m incl new investor HBM Healthcare Investments 2021-03-02
eGenesis–SEVERAL: investment, 202103 financing round Series C $125m from existing + new investors 2021-03-02
eGenesis–Wellington Partners: investment, 202103 financing round Series C totalling $125m incl existing investor Wellington Partners 2021-03-02
FogPharma–HBM: investment, 202103 financing round Series C totalling $107m incl new + co-investor HBM Healthcare Investments 2021-03-01
FogPharma–SEVERAL: investment, 202103 financing round Series C $107m led by VenBio Partners 2021-03-01
Kairos GmbH–Iqvia: investment, 202103 acquisition of Kairos GmbH by Iqvia 2021-03-01
PBD Biotech–SEVERAL: investment, 202103 financing round 2021-03-01
Silicon Therapeutics–Roivant: investment, 202102– acquisition $450m in shares + milestones by Roivant Sciences ANNOUNCED 2021-02-26
Orna Therapeutics–Novartis: investment, 202102 financing round Series A totalling $80m incl co-investor NIBR 2021-02-24
Orna Therapeutics–SEVERAL: investment, 202102 financing round Series A $80m led by MPM Capital + Taiho Ventures + F2 Ventures 2021-02-24
Tetramer Shop–10x Genomics: investment, 202102 acquisition €na of Tetramer Shop ApS by 10x Genomics Inc 2021-02-24
Vividion Therapeutics–SEVERAL: investment, 202102 financing round Series C $135m co-led by new investors Logos Capital + Boxer Capital 2021-02-24
Mosa Meat–SEVERAL: investment, 202102 financing round Series B 3rd + final closing $10m bringing total Series B to $85m 2021-02-23
Humacyte–Fresenius: investment, 202102–202108 PIPE financing totalling $175m at $10/share incl $25m from Fresenius Medial Care 2021-02-17
Humacyte–SEVERAL: investment, 202102–202108 SPAC merger listing at Nasdaq providing $245m with $70m cash held in AHAC plus $175m PIPE 2021-02-17
Humacyte–UBS: investment, 202102– PIPE financing totalling $175m at $10/share incl investor UBS O’Connor 2021-02-17
Ginolis–Cellink: investment, 202102–202103 acquisition 100% of Ginolis debt/cash-free for €65.7m with €41.6m in cash + €24.1m in shares 2021-02-15
Sophia Genetics–Gilmartin Group: public relations, 202102 service existent Gilmartin Group is investor contact 2021-02-11
Labster–SEVERAL: investment, 202102 financing round Series C $60m led by Andreessen Horowitz 2021-02-10
Labster–Swisscom: investment, 202102 financing round Series C totalling $60m incl existing + co-investor Swisscom Ventures 2021-02-10
MedLumics–Kurma Partners: investment, 202102 financing round totalling €18m incl new investor Kurma Partners 2021-02-10
MedLumics–SEVERAL: investment, 202102 financing round €18m led by Asabys Partners 2021-02-10
MedLumics–VI Partners: investment, 202102 financing round totalling €18m incl new investor VI Partners Swiss Innovation 2021-02-10
InfanDx–Akampion: public relations, 202102 service existent by Akampion 2021-02-04
Pharvaris–SEVERAL: investment, 202102 IPO $165.41m+$24.8m with 8.27m+1.24m ordinary shares at $20/share at Nasdaq Global Select Market 2021-02-04
Tecan–UgenTec: laboratory automation, 202102– collab product integration of Tecan workstations with FastFinder qPCR-s/w for sale in dx markets 2021-02-04
Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund 2021-02-03
Genopis–Wacker: investment, 202102 acquisition of Genopis Inc for $39m in cash + milestones from Helixmith Co Ltd + Medivate Partners LLC 2021-02-03
Carisma Therapeutics–Cevec: cell line technology, 202102– license €na for use of CAP technology to produce adenovirus vectors for cancer cell therapy 2021-02-02
Avacta–Adeptrix: MS-based SARS-CoV-2 test, 202101 collab existent developm of BAMS SARS-CoV-2 assay for research + IVD 2021-01-28
next pagenext page 1 2 3 ... 9 10 11 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] No Content Marketing 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top